share_log

Anavex Life Sciences Shares Are Trading Higher After the Company Announced New Data From the Phase IIb/III Study Showing That Blarcamesine, Once Daily Orally, Demonstrates Pre-specified Clinical Efficacy Through Upstream SIGMAR1 Activation.

Benzinga ·  Nov 1, 2024 02:58
Anavex Life Sciences Shares Are Trading Higher After the Company Announced New Data From the Phase IIb/III Study Showing That Blarcamesine, Once Daily Orally, Demonstrates Pre-specified Clinical Efficacy Through Upstream SIGMAR1 Activation.
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment